MarketVIEW: Allergic immunotherapy vaccines (CAT: VAMV012)

**Product Name**: MarketVIEW: Allergic immunotherapy vaccines

**Description**: Global vaccine commercial opportunity assessment

**Contents**: Executive presentation + 1 forecast model

**Therapeutic Area**: Immunotherapies

**Publication date**: July 2014

**Catalogue No**: VAMV012

**Background**

Allergy or Allergic rhinitis is caused by sensitivity to a number of environmental factors including grass, tree and weed pollens, house dust mite and cat dander. Prevalence in adults can range from 17 – 40% and is region/climate dependent. For those patients failing to respond to symptomatic treatments e.g. antihistamines Allergen-specific immunotherapy can be an effective alternative which involves long term treatment with SLIT or SCIT based products.

Current market leaders in Allergen-specific immunotherapies are ALK-Abello (Denmark) and Stallergenes (France) which are currently focused on both global expansion strategies for their existing products e.g. Grazax/Oralair but also new product development to address the major unmet need of a more convenient administration profile(s). In April 2014, Grazax (marketed as Grastek) and Ragwitek (ragweed) were approved in the US, where they are marketed by Merck & Co.

This updated MarketVIEW product is a comprehensive commercial opportunity assessment detailing the current market for Allergen-specific immunotherapies with a patient based value/volume forecast for all relevant allergens/administration routes to 2025. The model takes into account significant future events including penetration into new countries/regions and launch of new products. A discussion is also included with regard to latest epidemiology; review of regulatory/reimbursement/pricing issues and a focus on key early stage/late stage R&D development programs along with gap analysis.
Methodology

VacZine Analytics has closely monitored all significant source material pertaining to allergic rhinitis epidemiology/dynamics, current treatments and novel immunotherapeutics (pipeline). Allergens included have been grass, tree and weed pollens, house dust mite and cat dander. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by VacZine Analytics in field of immunotherapeutic vaccines has also been utilised. **See Bibliography for exact sources.**

PRODUCT CONTENTS:
Updated July 2014 (CAT No: VAMV012)

****This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

Authors Note
Executive summary
Differences from previous forecast: December 2011
Commercial model: key outputs
Global sales (€m) by region, 2010-25
Global sales (€m) by allergen, 2010-25
Global sales (€m) by route, 2010-25
Global number of patients treated, 2010-25
US sales (€m) by allergen, 2010-25
Europe sales (€m) by allergen, 2010-25
Japan sales (€m) by allergen, 2010-25
Markets covered and product launches
Key model assumptions per country
Model comparison (June 2013 vs. July 2014)
Allergic immunotherapies background
Allergic rhinitis disease burden: overview
Allergic rhinitis prevalence in Europe, US and Japan
Market dynamics: size and value
Market dynamics: immunotherapy sales by country
Market dynamics: immunotherapy sales by company
Market dynamics: product types
Market dynamics: immunotherapy sales by route
Market dynamics: key approvals
Market dynamics: comments on Grastek potential
Grazax and Oralair sales, 2008-13, Europe
Future market trends
Future market trends: SLIT-tablet product pipeline
Future market trends: recombinant immunotherapies
Methodology: allergic rhinitis prevalence and severity
Methodology: sensitization to inhaled allergens
Continued...........

Methodology: treatment inputs
Methodology: treatment pricing
Allergic immunotherapies: back-up/source material
Bibliography
Disclaimer
About VacZine Analytics

PAGES: ~60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based) – 1 model

Title sheet
CHARTS (Value)
Value summary per country
Value summary by allergen
Patients treated by country
Patients treated by allergen
Country models:
Adult/child
Germany
France
Spain
Italy
Netherlands
Other EU
UK
US
Japan
Other EU
Children
Germany
France
Spain
Italy
Netherlands
Other EU
UK
US
Japan
Other EU
Source material
Global pricing
Market data
Epi model inputs
Allergens
Epi model outputs
Population database

WORKSHEETS: ~65
PRODUCT COST:

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- USD $8995.00 / GBP £5450.00* (Region license)*

*Indicative rate only. Prevailing rate applied to date of transaction.
*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

---

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
**VacZine Analytics (R)** and the “spiral logo” are UK Registered Trademarks, 2009
TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009